Aberdeen Group
ALLO icon

Aberdeen Group’s Allogene Therapeutics ALLO Stock Holding History

Aberdeen Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4M Buy
5,001,752
+3,539,533
+242% +$7.77M 0.01% 586
2026
Q1 		$3.57M Sell
1,462,219
-624,113
-30% -$1.25M 0.01% 722
2025
Q4 		$2.86M Buy
2,086,332
+504,067
+32% +$665K ﹤0.01% 743
2025
Q3 		$1.96M Buy
1,582,265
+715,015
+82% +$852K ﹤0.01% 783
2025
Q2 		$980K Hold
867,250
– – ﹤0.01% 831
2025
Q1 		$1.27M Buy
867,250
+502,868
+138% +$948K ﹤0.01% 796
2024
Q4 		$776K Buy
+364,382
New +$899K ﹤0.01% 844

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Aberdeen Group's ALLO Position: Q2 2026 in Review

Aberdeen Group increased its Allogene Therapeutics (ALLO) stake by 242% in Q2 2026, buying an estimated $7.77M and bringing the position to 5,001,752 shares worth $10.4M. The position accounts for 0.01% of the portfolio, ranked #586.

Aberdeen Group first reported a position in ALLO in Q4 2024 and has held it in 7 quarters since. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Aberdeen Group held 5,001,752 shares of Allogene Therapeutics worth $10.4M as of Q2 2026.
  • Aberdeen Group bought 3,539,533 Allogene Therapeutics shares in Q2 2026, an estimated $7.77M.
  • Allogene Therapeutics made up 0.01% of Aberdeen Group's portfolio in Q2 2026, its #586 holding.
  • Aberdeen Group first reported a position in Allogene Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.